CLOUD

ARO-MUC5AC is being developed for the treatment of asthma. Asthma is a chronic respiratory disease characterized by narrowing of the airways, the tubes which carry air into the lungs, causing symptoms of wheezing, shortness of breath, chest tightness and/or cough. Mucus build-up in the airways often contributes to this narrowing. ARO-MUC5AC is being developed to treat patients with asthma by the reducing expression of MUC5AC protein in the lung. Since MUC5AC is an important component of airway mucus, it is possible that ARO-MUC5AC will decrease airway mucus build-up in patients with asthma. Decreased mucus may then result in better airflow, improved symptoms, and fewer disease exacerbations.

While ARO-MUC5AC is intended for use in asthma patients, these patients may have baseline lung problems and sometimes have escalations of their disease when they may become very ill and hence must change their medications to treat their worsening condition. For this reason, this study initially
evaluates each dose level in a healthy volunteer population to generate a baseline understanding of safety in a population with normal functions of their vital organs and who do not take any medications for any lung illnesses.

The research project is being conducted to:
1. Find if the study drug has any side-effects and is it well tolerated when given as a single dose in normal healthy volunteers (NHV)?
2. Find how much of the study drug gets into the blood stream, and how long does the body take to get rid of it?
3. Assess the effects of ARO-MUC5AC on lung function.

This study (2022 FULL 12482) is being funded by Arrowhead Pharmaceuticals Inc. and has been approved by the Health and Disability Ethics Committee.

Inpatient stay: 2 nights

Follow up: 5 visits

Reimbursement: $3,500 (less tax)